What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies.
Rupec. Rudolf A RA; Boneberger. Susanne S; Ruzicka. Thomas T
Key Findings
- Atopic dermatitis involves both genetic skin barrier defects (like filaggrin mutations) and immune system dysregulation.
- Antimicrobial peptides such as LL‑37 are down‑regulated in eczema‑affected skin.
- The exact contributions of lymphocytes, dendritic cells, and keratinocytes to skin immunity remain debated.
Practical Outcomes
- While the study doesn’t provide a direct protocol, it suggests that supporting skin barrier health and possibly boosting LL‑37 (e.g., through vitamin D or topical agents) could be beneficial for eczema management. However, more research is needed before recommending specific LL‑37 supplementation.
Summary
The abstract says that eczema (atopic dermatitis) is linked to genetics, skin barrier problems, and a messed‑up immune response, and that the skin’s natural antimicrobial peptide LL‑37 is lower in affected people. It doesn’t give a new treatment, just points out that LL‑37 and other defenses are part of the disease puzzle.
Abstract
The pathophysiology of atopic dermatitis is still under discussion. Although it is widely accepted that environmental factors and a genetic predisposition are essential, the role of the innate and adaptive immune system and the functional cascade of the cells involved is still unclear. A concept that integrates all immune cells as equally essential has allure. In addition, barrier abnormalities due to mutations of the gene coding for filaggrin and down-regulation of antimicrobial peptides, such as LL-37 and beta-defensins 2 and 3, were very recently found to be relevant for the pathogenesis of atopic dermatitis.
Study Information
pubmed
2010
10.1016/j.clindermatol.2009.04.004
23
59